AUBFM01 Phage as a Therapeutic Candidate Against MDR Acinetobacter baumannii: Characterization, and Immune-Aware Profiling
Microorganisms · 16.04.2026 · 14 (4) · 903
DOI: 10.3390/microorganisms14040903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 16.04.2026. Verfasst von Dina Kabbara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American University of Beirut.
Abstract (Originalsprache)
Multidrug-resistant Acinetobacter baumannii is a major nosocomial pathogen for which bacteriophages are being explored as alternative antibacterial agents. In this study, we isolated and characterized AUBFM01, a lytic phage active against MDR A. baumannii, and performed an initial assessment of its interaction with PMA-differentiated THP-1 macrophages. AUBFM01 was evaluated by host range testing, adsorption and one-step growth assays, lytic activity, stability testing, biofilm disruption, whole-genome sequencing, and flow cytometry-based macrophage profiling. The phage showed rapid adsorption, a short latent period of approximately 30 min, and a burst size of about 165 phage particles per infected cell. It remained stable under moderate temperature and near-neutral pH conditions and significantly reduced preformed A. baumannii biofilm biomass in vitro. Genomic analysis identified a 41,354-bp double-stranded DNA genome lacking detectable lysogeny-associated genes, antibiotic resistance determinants, and known bacterial virulence factors. In THP-1 macrophages, AUBFM01 exposure was associated with reduced cell viability and with enrichment of a resting/intermediate-like CD86-defined phenotype among the remaining cells, including after endotoxin reduction. These findings identify AUBFM01 as a lytic anti-Acinetobacter phage with antibiofilm activity and notable macrophage-associated effects that warrant further mechanistic and safety investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
- Center of Infectious Diseases Research, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
ORCID-Profile: Dina Kabbara, Tasnime A Abdo Ahmad, May F Mrad, Ghassan G Matar, Esber S Saba
Förderung
- American University of Beirut
Zitieren
APA
Kabbara, D., Nakib, L., Shokor, Z., Abdo Ahmad, T. A., Mrad, M. F., Matar, G. G., & Saba, E. S. (2026). AUBFM01 Phage as a Therapeutic Candidate Against MDR Acinetobacter baumannii: Characterization, and Immune-Aware Profiling. Microorganisms, 14(4), 903. https://doi.org/10.3390/microorganisms14040903
Vancouver
Kabbara D, Nakib L, Shokor Z, Abdo Ahmad TA, Mrad MF, Matar GG, et al. AUBFM01 Phage as a Therapeutic Candidate Against MDR Acinetobacter baumannii: Characterization, and Immune-Aware Profiling. Microorganisms. 2026;14(4):903. doi:10.3390/microorganisms14040903
BibTeX
@article{Kabbara2026,
author = {Kabbara, Dina and Nakib, Layane and Shokor, Zahraa and Abdo Ahmad, Tasnime A and Mrad, May F and Matar, Ghassan G and Saba, Esber S},
title = {AUBFM01 Phage as a Therapeutic Candidate Against MDR Acinetobacter baumannii: Characterization, and Immune-Aware Profiling},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {4},
pages = {903},
doi = {10.3390/microorganisms14040903}
}
EUVIMED